U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's DiseasePRNewsWire • 10/23/26
Forget Chasing 7% Yields: These 5 Dividend Stocks Offer Something Different24/7 Wall Street • 10/23/26
BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential?Zacks Investment Research • 10/23/26
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 10/23/26
AbbVie (ABBV) Is Considered a Good Investment by Brokers: Is That True?Zacks Investment Research • 10/22/26
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combinationReuters • 10/22/26
AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis SuppurativaPRNewsWire • 10/22/26
These 3 Dividend Stocks Paid Out Over 90% of Free Cash Flow, but 1 Has Raised Its Dividend 54 Years in a Row24/7 Wall Street • 10/22/26
AbbVie (ABBV) Stock Declines While Market Improves: Some Information for InvestorsZacks Investment Research • 10/21/26
Allergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa™ EvidencePRNewsWire • 10/21/26
AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 10/20/26
AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology CommunityPRNewsWire • 10/20/26
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 ResultsZacks Investment Research • 10/19/26
Big tech is wobbling. Goldman Sachs says it's time to buy these 23 unloved stocks instead.Market Watch • 10/19/26
AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's DiseasePRNewsWire • 10/19/26
AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor PortfolioPRNewsWire • 10/18/26